Viola Van Gorp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Viola Van Gorp has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Herbert D. Spapen
Department of Intensive Care, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium
39 shared publications - Patrick M. Honore
ICU Department, CHU UCL Godinne Namur, UCL Louvain Medical School, Yvoir, Belgium
34 shared publications Rita Jacobs
ICU Department Universitair Ziekenhuis Brussel Vrije Universiteit Brussel Brussels Belgium
27 shared publicationsElisabeth De Waele
ICU Department Universitair Ziekenhuis Brussel Vrije Universiteit Brussel Brussels Belgium
25 shared publicationsInne Hendrickx
ICU Department Universitair Ziekenhuis Brussel Vrije Universiteit Brussel Brussels Belgium
12 shared publicationsJouke De Regt
ICU Department Universitair Ziekenhuis Brussel Vrije Universiteit Brussel Brussels Belgium
12 shared publications
Latest Publications
- Open Access
- 13 December 2016
- Published by S. Karger AG in Blood Purification
- Vol. 43 (1-3) , 91-96
Statins and the Kidney: Friend or Foe?
Statins essentially are cholesterol-lowering drugs that are extensively prescribed for primary and secondary prevention of cardiovascular disease. Compelling evidence suggests that the beneficial effects of statins may not only be due to controlling cholesterol levels but also due to a pleiotropic cholesterol-independent anti-inflammatory, antioxidant, endothelial-protective and plaque-stabilizing activity. Along this line, statins may also exert acute and long-term effects on renal function. We present a narrative literature review that summarizes arguments in favour or against the preventive and/or therapeutic use of statins in kidney-related diseases or complications. We also highlight the ongoing controversy regarding statin therapy in chronic and end-stage kidney disease.
- 13 December 2016
- Published by S. Karger AG in Blood Purification
- Vol. 43 (1-3) , 91-96
Open AccessStatins and the Kidney: Friend or Foe?
Statins essentially are cholesterol-lowering drugs that are extensively prescribed for primary and secondary prevention of cardiovascular disease. Compelling evidence suggests that the beneficial effects of statins may not only be due to controlling cholesterol levels but also due to a pleiotropic cholesterol-independent anti-inflammatory, antioxidant, endothelial-protective and plaque-stabilizing activity. Along this line, statins may also exert acute and long-term effects on renal function. We present a narrative literature review that summarizes arguments in favour or against the preventive and/or therapeutic use of statins in kidney-related diseases or complications. We also highlight the ongoing controversy regarding statin therapy in chronic and end-stage kidney disease.
- Open Access
- 1 October 2016
- Published by Taylor & Francis in International Journal of Nephrology and Renovascular Disease
- Vol. ume 9, 253-256
Biomarkers in critical illness: have we made progress?
Biomarkers have emerged as exemplary key players in translational medicine. Many have been assessed for timely recognition, early treatment, and adequate follow-up for a variety of pathologies. Biomarker sensitivity has improved considerably over the last years but specificity remains poor, in particular when two “marker-sensitive” conditions overlap in one patient. Biomarker research holds an enormous potential for diagnostic and prognostic purposes in postoperative and critically ill patients who present varying degrees of inflammation, infection, and concomitant (sub)acute organ dysfunction or failure. Despite a remarkable progress in development and testing, biomarkers are not yet ready for routine use at the bedside.
- 1 October 2016
- Published by Taylor & Francis in International Journal of Nephrology and Renovascular Disease
- Vol. ume 9, 253-256
Open AccessBiomarkers in critical illness: have we made progress?
Biomarkers have emerged as exemplary key players in translational medicine. Many have been assessed for timely recognition, early treatment, and adequate follow-up for a variety of pathologies. Biomarker sensitivity has improved considerably over the last years but specificity remains poor, in particular when two “marker-sensitive” conditions overlap in one patient. Biomarker research holds an enormous potential for diagnostic and prognostic purposes in postoperative and critically ill patients who present varying degrees of inflammation, infection, and concomitant (sub)acute organ dysfunction or failure. Despite a remarkable progress in development and testing, biomarkers are not yet ready for routine use at the bedside.
- Open Access
- 26 December 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 1-2
Predicting acute kidney injury in severe trauma. A biomarker breakthrough?
- 26 December 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 1-2
Open AccessPredicting acute kidney injury in severe trauma. A biomarker breakthrough?
- Open Access
- 16 December 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 1-2
Peri-operative fluid strategy and post-operative acute kidney injury in cardiac surgery patients: any role for pre-operative statin therapy?
- 16 December 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 1-2
Open AccessPeri-operative fluid strategy and post-operative acute kidney injury in cardiac surgery patients: any role for pre-operative statin therapy?
- Open Access
- 12 December 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 1-2
Metabolic and coagulation effects of citrate: down to the last detail!
- 12 December 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 1-2
Open AccessMetabolic and coagulation effects of citrate: down to the last detail!
- Open Access
- 1 December 2015
- Published by Springer Nature in Critical Care
- Vol. 20 (1) , 14
Fondaparinux: another potential treatment for heparin-induced thrombocytopenia type II?
- 1 December 2015
- Published by Springer Nature in Critical Care
- Vol. 20 (1) , 14
Open AccessFondaparinux: another potential treatment for heparin-induced thrombocytopenia type II?
- Open Access
- 1 December 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 1
Presepsin and sepsis-induced acute kidney injury treated with continuous renal replacement therapy: will another promising biomarker bite the dust?
- 1 December 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 1
Open AccessPresepsin and sepsis-induced acute kidney injury treated with continuous renal replacement therapy: will another promising biomarker bite the dust?
- Open Access
- 1 December 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 426
Biomarker validity in the critically ill: all must face the (continuous) renal replacement challenge!
- 1 December 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 426
Open AccessBiomarker validity in the critically ill: all must face the (continuous) renal replacement challenge!
- Open Access
- 1 December 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 392
Is neutrophil gelatinase-associated lipocalin unaffected by convective continuous renal replacement therapy? Definitely … maybe
- 1 December 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 392
Open AccessIs neutrophil gelatinase-associated lipocalin unaffected by convective continuous renal replacement therapy? Definitely … maybe
- Open Access
- 1 December 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 386
Optimizing citrate dose for regional anticoagulation in continuous renal replacement therapy: measuring citrate concentrations instead of ionized calcium?
- 1 December 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 386
Open AccessOptimizing citrate dose for regional anticoagulation in continuous renal replacement therapy: measuring citrate concentrations instead of ionized calcium?